A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction

PURPOSE: This research examined the cost-effectiveness of adding empagliflozin to standard of care (SoC) compared with SoC alone for treatment of heart failure with reduced ejection fraction (HFrEF) from the perspective of healthcare payers in the United Kingdom (UK), Spain and France. METHODS: A li...

Descripción completa

Detalles Bibliográficos
Autores principales: Tafazzoli, Ali, Reifsnider, Odette S., Bellanca, Leana, Ishak, Jack, Carrasco, Marc, Rakonczai, Pal, Stargardter, Matthew, Linden, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550866/
https://www.ncbi.nlm.nih.gov/pubmed/36463524
http://dx.doi.org/10.1007/s10198-022-01555-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550866/
https://www.ncbi.nlm.nih.gov/pubmed/36463524
http://dx.doi.org/10.1007/s10198-022-01555-6

Ejemplares similares